伊伐布雷定联合比索洛尔在HFrEF患者急性期及易损期应用的疗效分析  

Efficacy Analysis of Ivabradine Combined with Bisoprolol in the Acute and Vulnerable Phases of HFrEF Patients

作　　者：任娟 梁晶星 田敏 罗仁[1] 陈劢[1] REN Juan;LIANG Jingxing;TIAN Min;LUO Ren;CHEN Mai(Cardiovascular Department,Ward One,First Division Hospital of Xinjiang Production and Construction Corps,Aksu 843000,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆生产建设兵团第一师医院心血管内科一病区,新疆维吾尔自治区阿克苏843000

出　　处：《系统医学》2025年第4期95-98,共4页Systems Medicine

基　　金：2021第一师医院院内课题(2021YNKY-12)。

摘　　要：目的分析伊伐布雷定联合比索洛尔在射血分数降低性心力衰竭(heart failure with reduced ejection fraction,HFrEF)患者心衰急性期及易损期的疗效。方法非随机选取2021年12月—2023年6月就诊于新疆生产建设兵团第一师医院的HFrEF患者为研究对象(104例)。根据治疗方案不同分为对照组(53例)和研究组(51例)。对照组使用比索洛尔,研究组使用伊伐布雷定联合比索洛尔。比较两组临床疗效。结果研究组总有效率为92.16%(47/51),高于对照组的79.24%(42/53),差异有统计学意义(χ^(2)=3.914,P<0.05)。与对照组相比,研究组静息心率、B型利钠肽水平及左室舒张末期直径更低,左室射血分数更高,差异有统计学意义(P均<0.05)。两组不良反应发生率及心血管不良事件的发生率比较,差异无统计学意义(P均>0.05)。结论在HFrEF患者急性期及易损期联合应用伊伐布雷定和比索洛尔,有利于改善临床症状,降低静息心率,改善心衰指标,逆转心室重建,且不会增加不良反应及心血管不良事件发生率。Objective To analyze the efficacy of ivabradine in combination with bisoprolol in patients with heart failure with reduced ejection fraction(HFrEF)in the acute and vulnerable stages.Methods A total of 104 patients with HFrEF admitted to the First Division Hospital of Xinjiang Production and Construction Corps from December 2021 to June 2023 were non-randomly selected as the research objects.They were divided into control group(53 cases)and study group(51 cases)according to different treatment plans.The control group received bisoprolol and the study group received ivabradine combined with bisoprolol.The clinical efficacy of the two groups was compared.Results The total effective rate of the study group was 92.16%(47/51),which was higher than 79.24%(42/53)of the control group,the difference was statistically significant(χ^(2)=3.914,P<0.05).Compared with the control group,the resting heart rate,B-type natriuretic peptide level and left ventricular end-diastolic diameter were lower in the study group,and left ventricular ejection fraction was higher,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions and cardiovascular adverse events between the two groups(both P>0.05).Conclusion The combination of Ivabridine and Bisoprool in the acute and vulnerable stages of HFrEF patients is beneficial to improve clinical symptoms,reduce resting heart rate,improve indicators of heart failure,reverse ventricular remodeling,and does not increase the incidence of adverse reactions and cardiovascular adverse events.

关 键 词：伊伐布雷定 比索洛儿 射血分数降低型心力衰竭 急性期 易损期 

分 类 号：R54[医药卫生—心血管疾病]